Singapore authorities now reviewing telemed providers’ ads for weight-loss drugs
Lawyers say such advertisements may contravene a ban on ads for prescription medications
SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, while lawyers say that the providers could be in breach of a ban on advertisements of prescription-only medicines.
The telemedicine providers have put out ads for glucagon-like peptide 1 agonists, or GLP-1s, a class of drugs that are used to treat Type 2 diabetes but have gained attention for their effectiveness in aiding weight loss.
In response to queries, the Ministry of Health and the Health Sciences Authority said that they are reviewing the ads flagged by The Business Times and will take “appropriate enforcement action if any contraventions are detected”.
TRENDING NOW
Prima to move out of historic Keppel Road flour mill building in 2028
Grab CEO’s wife Chloe Tong on life with Anthony Tan and finding her purpose
OCBC sheds S$8 billion in value as shares close nearly 6% down; analysts cautious on banks
As Asia’s food delivery giants rejig the pie, who will win the market?
